No adjustment vs. adjustment formula as input weight for propofol target-controlled infusion in morbidly obese patients

European Journal of Anaesthesiology

Volumn 26, Issue 5, 2009, Pages 362-369

  Colla, Luca La ^a   Albertin, Andrea ^b   Colla, Giorgio La ^c   Ceriani, Valerio ^b   Lodi, Tiziana ^b   Porta, Andrea ^b   Iorgio Aldegheri, G ^b   Mangano, Alberto ^a   Khairallah, Ilias ^c   Fermo, Isabella ^d  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Anaesthesia; Intravenous; Obesity; Propofol

Indexed keywords

PROPOFOL; INTRAVENOUS ANESTHETIC AGENT;

ADULT; ANESTHESIA INDUCTION; ARTICLE; BISPECTRAL INDEX; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG INFUSION; FEMALE; HUMAN; MALE; MORBID OBESITY; RANDOMIZED CONTROLLED TRIAL; BIOLOGICAL MODEL; DOSE RESPONSE; ELECTROENCEPHALOGRAPHY; INTRAVENOUS ANESTHESIA; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; ANESTHESIA, INTRAVENOUS; ANESTHETICS, INTRAVENOUS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OBESITY, MORBID; PROPOFOL; PROSPECTIVE STUDIES;

EID: 70149104344     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0b013e328326f7d0     Document Type: Article

References (25)

1. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894:i-xii, 1 -253.
2. Adams JP, Murphy PG. Obesity in anaesthesia and intensive care. Br J Anaesth 2000; 85:91-108.
3. Alexander JK. Obesity and circulation. Mod Concepts Cardiovasc Dis 1963; 32:799-803.
4. Agarwal N, Shibutani K, SanFilippo JA, Del Guercio LR. Hemodynamic and respiratory changes in surgery of the morbidly obese. Surgery 1982; 92:226-234.
5. Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001; 12:1211-1217.
6. Alvarez AO, Cascardo A, Albarracin Menendez S, et al. Total intravenous anesthesia with midazolam, remifentanil, propofol and cistracurium in morbid obesity. Obes Surg 2000; 10:353-360.
7. Marsh B, White M, Morton N, Kenny GN. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth 1991; 67:41-48.
8. Hirota K,Ebina T,Sato T,et al.Istota lbody weight an appropriate predictor for propofol maintenance dose? Acta Anaesthesiol Scand 1999; 43:842-844.
9. Chassard D, Berrada K, Bryssine B, et al. Influence of body compartments on propofol induction dose in female patients. Acta Anaesthesiol Scand 1996; 40:889-891.
10. Bouillon T,Shafer SL.Doessizematter?Anesthesiology 1998;89:557- 560.
11. Gepts E. Pharmacokinetic concepts for TCI anaesthesia. Anaesthesia 1998; 53 (Suppl 1):4-12.
12. De Baerdemaeker LEC, Mortier EP, Struys MMRF. Pharmacokinetics in obese patients. Cont Educ Anaesth Crit Care Pain 2004; 4:152-155.
13. Albertin A, Poli D, La Colla L, et al. Predictive performance of 'Servin's formula' during BIS-guided propofol-remifentanil target-controlled infusion in morbidly obese patients. Br J Anaesth 2007; 98:66-75.
14. Lemmens HJ, Brodsky JB, Bernstein DP. Estimating ideal body weight - a new formula. Obes Surg 2005; 15:1082-1083.
15. Servin F, Farinotti R, Haberer JP, Desmonts JM. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology 1993; 78:657-665.
16. Plummer GF. Improved method for the determination of propofol in blood by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987; 421:171-176.
17. Varvel JR, Donoho DL, Shafer SL. Measuring the predictive performance of computer-controlled infusion pumps. J Pharmacokinet Biopharm 1992; 20:63-94.
18. Barvais L, Rausin I, Glen JB, et al. Administration of propofol by target- controlled infusion in patients undergoing coronary artery surgery. J Cardiothorac Vasc Anesth 1996; 10:877-883.
19. Coetzee JF, Glen JB, Wium CA, Boshoff L. Pharmacokinetic model selection for target controlled infusions of propofol. Assessment of three parameter sets. Anesthesiology 1995; 82:1328-1345.
20. Swinhoe CF, Peacock JE, Glen JB, Reilly CS. Evaluation of the predictive performanceofa'Diprifusor'TCIsystem.Anaesthesia 1998;53 (Suppl 1): 61 -67.
21. Egan TD, Huizinga B, Gupta SK, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 1998; 89:562-573.
22. Shafer A, Doze VA, Shafer SL, White PF. Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. Anesthesiology 1988; 69:348-356.
23. Schuttler J, Kloos S, Schwilden H, Stoeckel H. Total intravenous anaesthesia with propofol and alfentanil by computer-assisted infusion. Anaesthesia 1988; 43 (Suppl):2-7.
24. Glass PSA, Shafer SL, Reves JG. Intravenous drug delivery systems. In: Miller RD, editor. Anesthesia, 6th ed. New York: Churchill Livingstone; 2006.
25. Mertens MJ, Olofsen E, Burm AG, et al. Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. Anesthesiology 2004; 100:795-805.